ORCID Profile
0000-0002-0669-6358
Current Organisation
Shanghai Enflame Technology Co Ltd
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: American Association for Cancer Research (AACR)
Date: 04-03-2023
DOI: 10.1158/1078-0432.22472364
Abstract: Association between SChLAP1 expression and clinicopathological factors in glioma
Publisher: MDPI AG
Date: 15-07-2022
Abstract: Routine examination of entire histological slides at cellular resolution poses a significant if not insurmountable challenge to human observers. However, high-resolution data such as the cellular distribution of proteins in tissues, e.g., those obtained following immunochemical staining, are highly desirable. Our present study extends the applicability of the PathoFusion framework to the cellular level. We illustrate our approach using the detection of CD276 immunoreactive cells in glioblastoma as an ex le. Following automatic identification by means of PathoFusion’s bifocal convolutional neural network (BCNN) model, in idual cells are automatically profiled and counted. Only discriminable cells selected through data filtering and thresholding were segmented for cell-level analysis. Subsequently, we converted the detection signals into the corresponding heatmaps visualizing the distribution of the detected cells in entire whole-slide images of adjacent H& E-stained sections using the Discrete Wavelet Transform (DWT). Our results demonstrate that PathoFusion is capable of autonomously detecting and counting in idual immunochemically labelled cells with a high prediction performance of 0.992 AUC and 97.7% accuracy. The data can be used for whole-slide cross-modality analyses, e.g., relationships between immunochemical signals and anaplastic histological features. PathoFusion has the potential to be applied to additional problems that seek to correlate heterogeneous data streams and to serve as a clinically applicable, weakly supervised system for histological image analyses in (neuro)pathology.
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22472361
Abstract: Proteins binding with SChLAP1 sense and antisense
Publisher: Elsevier BV
Date: 04-2022
Publisher: Elsevier BV
Date: 07-2021
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22472352.V1
Abstract: Association between ACTN4 expression and clinicopathological factors in glioma
Publisher: American Association for Cancer Research (AACR)
Date: 15-11-2019
DOI: 10.1158/1078-0432.CCR-19-0747
Abstract: Long noncoding RNAs (lncRNA) have essential roles in erse cellular processes, both in normal and diseased cell types, and thus have emerged as potential therapeutic targets. A specific member of this family, the SWI/SNF complex antagonist associated with prostate cancer 1 (SChLAP1), has been shown to promote aggressive prostate cancer growth by antagonizing the SWI/SNF complex and therefore serves as a biomarker for poor prognosis. Here, we investigated whether SChLAP1 plays a potential role in the development of human glioblastoma (GBM). RNA-ISH and IHC were performed on a tissue microarray to assess expression of SChLAP1 and associated proteins in human gliomas. Proteins complexed with SChLAP1 were identified using RNA pull-down and mass spectrometry. Lentiviral constructs were used for functional analysis in vitro and in vivo. SChLAP1 was increased in primary GBM s les and cell lines, and knockdown of the lncRNA suppressed growth. SChLAP1 was found to bind heterogeneous nuclear ribonucleoprotein L (HNRNPL), which stabilized the lncRNA and led to an enhanced interaction with the protein actinin alpha 4 (ACTN4). ACTN4 was also highly expressed in primary GBM s les and was associated with poorer overall survival in glioma patients. The SChLAP1–HNRNPL complex led to stabilization of ACTN4 through suppression of proteasomal degradation, which resulted in increased nuclear localization of the p65 subunit of NF-κB and activation of NF-κB signaling, a pathway associated with cancer development. Our results implicated SChLAP1 as a driver of GBM growth as well as a potential therapeutic target in treatment of the disease.
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22472379.V1
Abstract: Authorship Change forms
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22472373.V1
Abstract: Supplementary Materials and Methods
Publisher: IEEE
Date: 13-12-2020
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22472358.V1
Abstract: Most significant decreasing protein partners of HNRNPL after SChLAP1 knockdown
Publisher: MDPI AG
Date: 04-02-2021
Abstract: We have developed a platform, termed PathoFusion, which is an integrated system for marking, training, and recognition of pathological features in whole-slide tissue sections. The platform uses a bifocal convolutional neural network (BCNN) which is designed to simultaneously capture both index and contextual feature information from shorter and longer image tiles, respectively. This is analogous to how a microscopist in pathology works, identifying a cancerous morphological feature in the tissue context using first a narrow and then a wider focus, hence bifocal. Adjacent tissue sections obtained from glioblastoma cases were processed for hematoxylin and eosin (H& E) and immunohistochemical (CD276) staining. Image tiles cropped from the digitized images based on markings made by a consultant neuropathologist were used to train the BCNN. PathoFusion demonstrated its ability to recognize malignant neuropathological features autonomously and map immunohistochemical data simultaneously. Our experiments show that PathoFusion achieved areas under the curve (AUCs) of 0.985 ± 0.011 and 0.988 ± 0.001 in patch-level recognition of six typical pathomorphological features and detection of associated immunoreactivity, respectively. On this basis, the system further correlated CD276 immunoreactivity to abnormal tumor vasculature. Corresponding feature distributions and overlaps were visualized by heatmaps, permitting high-resolution qualitative as well as quantitative morphological analyses for entire histological slides. Recognition of more user-defined pathomorphological features can be added to the system and included in future tissue analyses. Integration of PathoFusion with the day-to-day service workflow of a (neuro)pathology department is a goal. The software code for PathoFusion is made publicly available.
Publisher: IEEE
Date: 13-12-2020
Publisher: Institute of Electrical and Electronics Engineers (IEEE)
Date: 06-2021
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22472364.V1
Abstract: Association between SChLAP1 expression and clinicopathological factors in glioma
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22472358
Abstract: Most significant decreasing protein partners of HNRNPL after SChLAP1 knockdown
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22472379
Abstract: Authorship Change forms
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.C.6528201
Abstract: AbstractPurpose: Long noncoding RNAs (lncRNA) have essential roles in erse cellular processes, both in normal and diseased cell types, and thus have emerged as potential therapeutic targets. A specific member of this family, the SWI/SNF complex antagonist associated with prostate cancer 1 ( i SChLAP1 /i ), has been shown to promote aggressive prostate cancer growth by antagonizing the SWI/SNF complex and therefore serves as a biomarker for poor prognosis. Here, we investigated whether i SChLAP1 /i plays a potential role in the development of human glioblastoma (GBM). Experimental Design: RNA-ISH and IHC were performed on a tissue microarray to assess expression of i SChLAP1 /i and associated proteins in human gliomas. Proteins complexed with i SChLAP1 /i were identified using RNA pull-down and mass spectrometry. Lentiviral constructs were used for functional analysis i in vitro /i and i in vivo /i . Results: i SChLAP1 /i was increased in primary GBM s les and cell lines, and knockdown of the lncRNA suppressed growth. i SChLAP1 /i was found to bind heterogeneous nuclear ribonucleoprotein L (HNRNPL), which stabilized the lncRNA and led to an enhanced interaction with the protein actinin alpha 4 (ACTN4). i ACTN4 /i was also highly expressed in primary GBM s les and was associated with poorer overall survival in glioma patients. The i SChLAP1 /i –HNRNPL complex led to stabilization of ACTN4 through suppression of proteasomal degradation, which resulted in increased nuclear localization of the p65 subunit of NF-κB and activation of NF-κB signaling, a pathway associated with cancer development. Conclusions: Our results implicated i SChLAP1 /i as a driver of GBM growth as well as a potential therapeutic target in treatment of the disease. /
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22472376
Abstract: Supplementary Figures S1-S7
Publisher: Elsevier BV
Date: 02-2023
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22472352
Abstract: Association between ACTN4 expression and clinicopathological factors in glioma
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22472373
Abstract: Supplementary Materials and Methods
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22472370
Abstract: Clinical data for in idual patients
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.C.6528201.V1
Abstract: AbstractPurpose: Long noncoding RNAs (lncRNA) have essential roles in erse cellular processes, both in normal and diseased cell types, and thus have emerged as potential therapeutic targets. A specific member of this family, the SWI/SNF complex antagonist associated with prostate cancer 1 ( i SChLAP1 /i ), has been shown to promote aggressive prostate cancer growth by antagonizing the SWI/SNF complex and therefore serves as a biomarker for poor prognosis. Here, we investigated whether i SChLAP1 /i plays a potential role in the development of human glioblastoma (GBM). Experimental Design: RNA-ISH and IHC were performed on a tissue microarray to assess expression of i SChLAP1 /i and associated proteins in human gliomas. Proteins complexed with i SChLAP1 /i were identified using RNA pull-down and mass spectrometry. Lentiviral constructs were used for functional analysis i in vitro /i and i in vivo /i . Results: i SChLAP1 /i was increased in primary GBM s les and cell lines, and knockdown of the lncRNA suppressed growth. i SChLAP1 /i was found to bind heterogeneous nuclear ribonucleoprotein L (HNRNPL), which stabilized the lncRNA and led to an enhanced interaction with the protein actinin alpha 4 (ACTN4). i ACTN4 /i was also highly expressed in primary GBM s les and was associated with poorer overall survival in glioma patients. The i SChLAP1 /i –HNRNPL complex led to stabilization of ACTN4 through suppression of proteasomal degradation, which resulted in increased nuclear localization of the p65 subunit of NF-κB and activation of NF-κB signaling, a pathway associated with cancer development. Conclusions: Our results implicated i SChLAP1 /i as a driver of GBM growth as well as a potential therapeutic target in treatment of the disease. /
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22472376.V1
Abstract: Supplementary Figures S1-S7
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22472370.V1
Abstract: Clinical data for in idual patients
Publisher: IEEE
Date: 11-2017
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22472361.V1
Abstract: Proteins binding with SChLAP1 sense and antisense
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22472367.V1
Abstract: Oligonucleotide sets used, Plasmids used and Primer sets used in this study
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22472367
Abstract: Oligonucleotide sets used, Plasmids used and Primer sets used in this study
No related grants have been discovered for Guoqing Bao.